TOtal tRansfemoral branCHed endovasCular tHoracoabdominal Aortic Repair Registry

A Physician-initiated, National, Multicentre, Ambispective, Observational Registry of Patients Undergoing Branched Endovascular Aortic Procedures With a Total Transfemoral Approach. (TORCH2 Registry)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04930172

Enrollment

100

Registered

2021-06-18

Start date

2022-10-30

Completion date

2022-10-30

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Aneurysm, Abdominal, Aortic Aneurysm, Thoracic

Brief summary

The purpose of the registry is to evaluate the peri-operative, short-, and mid- outcomes of endovascular treatment of thoracoabdominal aneurysms with multibranched endografts via total transfemoral approach for visceral vessels cannulation using steerable sheaths

Interventions

DEVICESteerable introducers

endografts via total transfemoral approach for visceral vessels cannulation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patient adult ( ≥18 years) of either sex, * patients who underwent a complex aortic procedure requiring a branched endograft via total transfemoral approach in the centers involved in the TORCH2 Registry

Exclusion criteria

* patients who did not receive treatment via total transfemoral approach, * patient with bleeding diathesis or coagulopathy, * patients with active systemic or cutaneous infection or inflammation, * patients who are pregnant or lactating, * patient younger than 18 years of age. * Absence of at least one imaging follow-up within the first post-operative year

Design outcomes

Primary

Measure	Time frame	Description
technical success	30 days	successful bridging stent graft deployment of all vessels, with aneurysm exclusion, without any signs of type I or type III endoleak, and with no evidence of stenosis/occlusion and mating stent dislocation/kinking at intraoperative completion angiography.
branch instability	30 days	freedom from any branch related complications and/or required reinterventions
clinical success	30 days	absence of death, type I/III endoleak, graft infection/thrombosis, aneurysm expansion and/or rupture, conversion to open repair, or new treatment-related thoracoabdominal pathologies

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026